Abstract:Background Few studies have evaluated the treatment of immunoglobulin A nephropathy (IgAN) patients with nephrotic syndrome (NS) and mesangioproliferative glomerulonephritis (MPGN). The aim of this study was to compare the therapeutic effects of oral glucocorticoids (GCS) combined with intravenous cyclophosphamide (CTX) and oral GCS alone in the treatment of the MPGN-IgAN patients with NS. Methods Biopsy-proven primary IgAN patients who were aged & GE;14 years at diagnosis, had coexistent NS and MPGN and estimated glomerular filtration rate (eGFR) & GE;15 mL/min/1.73 m(2), and were treated by oral GCS combined with intravenous CTX or oral GCS alone for 6-12 months were retrospectively included. The patients in the GCS + CTX (prednisone 0.6-0.8 mg/kg/day and intravenous CTX 0.6-1.0 g monthly) or GCS (prednisone 0.8-1 mg/kg/day) group were rather matched at a 1:1 ratio on key characteristics by propensity score matching. The primary outcome was defined as either complete remission or partial remission at Month 24. The secondary outcome was a composite renal endpoint defined as a 50% decline in eGFR, doubling of serum creatinine or progression to end-stage kidney disease. Results Among the 146 IgAN patients who met the inclusion criteria, 42 patients were enrolled in the GCS + CTX group, and 42 patients were enrolled in the GCS group after propensity score matching. The clinical and histological parameters were similar between the two groups. Remission occurred more frequently in the GCS + CTX group at Month 6 (88.1% vs 52.4%, P < 0.001), Month 12 (88.1% vs 56.1%, P = 0.001) and Month 24 (85.0% vs 47.5%, P < 0.001) than in the GCS group. Moreover, subgroup analysis revealed that the higher response rate at Month 24 in the GCS + CTX group than in the GCS group was also present in different subgroups defined by sex, age, eGFR or Oxford MEST-C. Notably, we found that eGFR decreased at a lower rate in patients from the GCS + CTX group than in patients from the GCS group [eGFR slope: 0.05(-3.09, 3.67) vs -2.56 (-11.30, 0.86) mL/min/1.73 m(2)/year, P = 0.03]. Based on multivariate Cox regression analysis, GCS + CTX treatment was found to be independently associated with a decrease in risk for the composite endpoint after adjusted by the International Risk Prediction Score with race (hazard ratio = 0.17, 95% confidence interval 0.04-0.83, P = .03). There was no significant difference in adverse events (50.0% vs 42.9%, P = 0.51) or serious adverse events (7.1% vs 11.9%, P = .71) between the two groups. Conclusions Oral GCS combined with intravenous CTX is superior to GCS alone in treating MPGN-IgAN patients combined with NS. As the retrospective design and small sample size, our findings need to be validated by a prospective study. Lay Summary Immunoglobulin A nephropathy (IgAN) is the leading cause of end-stage renal disease in youth worldwide. Nephrotic syndrome (NS) is a relatively rare condition in IgAN patients, accounting for approximately 5%-15% of all IgAN patients. There are two common pathological types of IgAN with NS, minimal-change disease (MCD-IgAN) and mesangioproliferative glomerulonephritis (MPGN-IgAN). The former has been shown to respond well to glucocorticoids (GCS) and is suggested to be treated as MCD based on the 2021 KDIGO guidelines. However, the treatment strategy for the latter is not clear since there have been few studies discussing treatment options for MPGN-IgAN patients. This is the first study to compare the efficacy and safety of GCS combined with cyclophosphamide (CTX) versus GCS alone for the treatment in patients with MPGN-IgAN combined with NS. We found that the combination of GCS and CTX was more effective in reducing urinary protein than GCS alone. Furthermore, we determined that GCS combined with CTX was associated with a reduced risk of renal function deterioration in the treatment of MPGN-IgAN patients with NS. Finally, we found there was no significant difference of adverse events between the two treatment groups. In conclusion, oral GCS combined with intravenous CTX is superior to GCS alone in treating MPGN-IgAN patients combined with NS. Our study provides important evidence for the treatment of IgAN patients with NS and MPGN.

Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy

Combined Immunosuppressive Treatment (CIST) in Lupus Nephritis: a Multicenter, Randomized Controlled Study.

Corticosteroids Improve Renal Survival: A Retrospective Analysis From Chinese Patients With Early-Stage IgA Nephropathy

Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria

Efficacy and Safety of Glucocorticoids Therapy for IgA Nephropathy: a Meta-Analysis of Randomized Controlled Trials.

Comparison Of Glucocorticoids Alone And Combined With Cyclosporine A In Patients With Iga Nephropathy: A Prospective Randomized Controlled Trial

Corticosteroids Could Improve the Renal Outcome of IgA Nephropathy with Moderate Proteinuria

A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study

Efficacy of Prednisone Combined with Mycophenolate Mofetil for Immunoglobulin A Nephropathy with Moderate-to-severe Renal Dysfunction

Prognosis of IgA Nephropathy with Stage 3b-5 CKD

Immunosuppressant Agents as Add-On Therapy Failed to Improve the Outcome of Immunoglobulin A Nephropathy with Crescent Score C1

Immunosuppressants or Corticosteroids Compared with Supportive Therapy: a Systematic Review and Meta-Analysis on the Efficacy and Safety for IgA Nephropathy Treatment.

Immunosuppression versus Supportive Care on Kidney Outcomes in IgA Nephropathy in the Real-World Setting

The Efficacy and Safety of Immunosuppressive Therapies in the Treatment of IgA Nephropathy: A Network Meta-Analysis.

Meta analysis for the long-term efficacy and safety of immunosuppression on the progression of IgA nephropathy

The long-term efficacy and safety of immunosuppressive therapy on the progression of IgA nephropathy: a meta-analysis of controlled clinical trials with more than 5-year follow-up.

Prednisone plus cyclophosphamide therapy for IgA nephropathy patients with impaired renal function and nephrotic syndrome

Oral Glucocorticoids with Intravenous Cyclophosphamide or Oral Glucocorticoids Alone in the Treatment of IgA Nephropathy Present with Nephrotic Syndrome and Mesangioproliferative Glomerulonephritis.

Improved Clinical Outcomes in Chinese Renal Allograft Recipients Receiving Lower Dose Immunosuppressants

Immunosuppressive agents in the treatment of IgA nephropathy: A meta-analysis of clinical randomized controlled literature

Steroids in the Treatment of IgA Nephropathy to the Improvement of Renal Survival: A Systematic Review and Meta-Analysis